Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
David Miles(Guy's Hospital), Gilles Romieu(Institut de Cancérologie de l'Ouest), Luc Dirix(GZA Ziekenhuizen Campus Sint-Augustinus), Nadia Harbeck(Breast Center), Joohyuk Sohn(Yonsei University), Guenther G. Steger(Mount Vernon Hospital), Louise Provencher(Mount Vernon Hospital), Xavier Pivot(Levi Strauss (United States)), T. Delozier(Mount Vernon Hospital), Javier Cortés(Villa Maria Hospital), Andrew Wardley(UK Research and Innovation), Piotr Tomczak(Mount Vernon Hospital), A. Chlistalla(Mount Vernon Hospital), Arlene Chan(Curtin University), Andreas Schneeweiß(German Cancer Research Center), Fabio Puglisi(University of Udine)
Cited by 887
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Breast cancer
|The Lancet|2016|2.3k